Colorectal Cancer Coalition

FDA approves highly concentrated liquid morphine for severe pain

In good news for cancer patients at the end of life,  the Food and Drug Administration has approved a concentrated liquid morphine to relieve acute and chronic pain in patients where other opiates are no longer working.

Although concentrated doses of liquid morphine have used to manage pain for opiate-tolerant patients for some time, the oral concentrated dose was not FDA approved.

The FDA has worked with Roxane Laboratories, the only manufacturer of the 20mg/mL formulation, to be sure that adequate supplies are available to patients in need. 

The action is part of the FDA unapproved drugs initiative.

As part of the unapproved drugs initiative, the FDA had previously sent warning letters to companies that manufactured and distributed  concentrated liquid morphine. After hospice programs and others who help patients at the end of life expressed serious concerns about not having the liquid morphine for cancer patients who could no longer swallow pills, FDA put the ban on hold until the medicines could get approval.

In announcing the approval, Douglas Throckmorton, M.D., deputy director for the FDA’s Center for Drug Evaluation and Research said,

An important goal of the unapproved drugs initiative is to make sure that marketed drugs meet current FDA standards. Our action today reflects a careful balance between ensuring patient access to necessary medicines, while making sure companies comply with the law.

This news article was originally posted on January 29th, 2010 and was accurate at the time of publication. Since then, information may have changed or links may now be outdated. Please call our Answer Line 1-877-427-2111 for the latest information, or talk to your doctor before making any medical decisions.

Posted by Kate Murphy on January 29th, 2010
Tags: FDA, liquid opiates

Leave a Comment Comments RSS

Your comments are welcome. However, specific medical advice will not be provided, and we urge you to consult with a qualified physician for diagnosis and for answers to your personal questions. C3 is not responsible for the medical accuracy of any comments left by persons other than C3 staff members. C3 staff members monitor comments and may respond publicly where appropriate.

Please note that we automatically publish the name that you enter next to your post. Also note that our pages are automatically indexed by Google and other search engines, and your name may therefore appear in search results on those sites. So if you wish to remain anonymous please use a different name or enter 'Anon' as the name.

We regret that we are unable to privately answer questions left as comments. So please do not include your phone number, email or mailing address in the body of your comment. For the best personal and direct response to your colorectal cancer treatment questions, please call our Answer Line at 1-877-4CRC-111 (1-877-427-2111).

Name Email (hidden) URL Comments (Basic HTML is allowed - a href, strong, em, blockquote)